Daiichi Life Insurance Co. Ltd. Acquires New Stake in Ventas, Inc. $VTR

Key Points

• Daiichi Life Insurance acquired 28,452 shares of Ventas in the second quarter, worth approximately $2.53 million. Institutional investors collectively own 94.18% of the healthcare REIT.
• Ventas shares opened at $93.32, near the upper end of their 12-month range. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.97 EPS and $1.73 billion in revenue, up 21.7% year over year.
• Analyst sentiment remains positive, with 15 Buy ratings and three Holds, resulting in a “Moderate Buy” consensus and an average price target of $98.00.

Daiichi Life Insurance Co. Ltd. bought a new position in Ventas, Inc. (NYSE:VTR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,452 shares of the real estate investment trust's stock, valued at approximately $2,527,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Ventas by 3.2% in the 4th quarter. Vanguard Group Inc. now owns 75,948,003 shares of the real estate investment trust's stock valued at $5,876,856,000 after buying an additional 2,349,176 shares during the last quarter. BlackRock Inc. acquired a new position in Ventas during the 2nd quarter worth approximately $4,953,439,000. State Street Corp boosted its position in Ventas by 2.5% during the 4th quarter. State Street Corp now owns 29,662,635 shares of the real estate investment trust's stock worth $2,309,234,000 after acquiring an additional 735,620 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Ventas by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 12,988,943 shares of the real estate investment trust's stock worth $1,001,447,000 after acquiring an additional 475,633 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Ventas by 27.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,176,254 shares of the real estate investment trust's stock worth $710,060,000 after acquiring an additional 2,000,341 shares in the last quarter. Institutional investors and hedge funds own 94.18% of the company's stock.

Ventas Trading Up 0.3%

Shares of Ventas stock opened at $93.32 on Monday. Ventas, Inc. has a 12-month low of $66.38 and a 12-month high of $101.60. The stock has a market cap of $47.87 billion, a P/E ratio of 172.81, a P/E/G ratio of 2.15 and a beta of 0.69. The company has a quick ratio of 0.44, a current ratio of 0.44 and a debt-to-equity ratio of 0.86. The business's 50 day moving average is $91.36 and its 200-day moving average is $87.15.

Ventas (NYSE:VTR - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. The company had revenue of $1.73 billion for the quarter, compared to analyst estimates of $1.68 billion. Ventas had a net margin of 4.08% and a return on equity of 1.99%. Ventas's revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 EPS. Equities research analysts predict that Ventas, Inc. will post 3.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ventas news, Director Michael J. Embler purchased 2,500 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $78.81 per share, with a total value of $197,025.00. Following the completion of the transaction, the director directly owned 19,202 shares in the company, valued at $1,513,309.62. This represents a 14.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on VTR. Weiss Ratings upgraded shares of Ventas from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, July 21st. JPMorgan Chase & Co. raised their target price on shares of Ventas from $93.00 to $94.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Cantor Fitzgerald lifted their price target on shares of Ventas from $97.00 to $102.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Mizuho boosted their price target on shares of Ventas from $98.00 to $104.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 22nd. Finally, Evercore reissued an "outperform" rating and set a $95.00 price target on shares of Ventas in a research report on Wednesday, April 29th. Fifteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Ventas presently has an average rating of "Moderate Buy" and an average target price of $98.00.

Ventas Company Profile

Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas' business model combines property ownership with active asset management and capital markets activity.

Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source